Merck Stock Hits New 52-Week High: What's Driving the Rally?

Impact · against what's priced in

The Phase 3 INTerpath-001 data is a positive clinical milestone but provides no immediate catalyst for MRK or MRNA as their current valuations already assume the commercial success of this specific vaccine combo. For BMY, the news reinforces the competitive threat to its oncology franchise from Merck's expanding label.

MRK+0.00

Already priced in

The price assumes

The assumption that positive Phase 3 recurrence-free survival data will translate into broad regulatory approval